Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor...

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Systemic steroids are a common treatment for immune-related adverse events (irAEs) during immune checkpoint inhibitor (ICI) therapy.
• The impact of steroid timing on ICI therapy outcomes and patient survival remains unclear.

Purpose of the Study:

• To investigate the association between systemic steroid use, steroid timing, and overall survival in patients receiving ICI therapy for cancer.

Main Methods:

• A multicenter retrospective cohort study of 20,163 veterans treated with ICIs between 2010 and 2021.
• Patients were categorized into groups based on steroid use (none, for irAEs, for non-irAE reasons).
• Overall survival was analyzed using Kaplan-Meier methods and Cox proportional hazard regression.

Main Results:

• Patients with irAEs had significantly improved overall survival (OS) compared to those without.
• Systemic steroids for irAEs were associated with improved OS compared to non-irAE steroid use or no steroid use.
• Early steroid use (<2 months post-ICI initiation) was associated with reduced survival benefit, irrespective of ICI continuation.

Conclusions:

• Steroid management of irAEs may not abrogate the survival benefits associated with ICIs.
• Early administration of systemic steroids (<2 months) following ICI initiation is linked to shorter survival, even with continued ICI therapy.